Ibnsina Pharma - Laporan Laba Rugi (TTM)

Ibnsina Pharma
EG ˙ CASE ˙ EGS512O1C012
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Ibnsina Pharma menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 18,373 18,679 18,992 19,929 20,730 21,733 22,309 21,870 21,792 22,264 23,775 26,700 30,258 33,949 37,682 42,066 48,546 55,842 62,312 68,074
Change (%) 1.67 1.68 4.93 4.02 4.84 2.65 -1.97 -0.36 2.17 6.78 12.30 13.33 12.20 10.99 11.63 15.40 15.03 11.58 9.25
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 16,835 17,212 17,498 18,402 19,147 20,103 20,657 20,234 20,224 20,648 22,008 24,669 27,982 31,434 34,934 38,922 44,882 51,446 57,267 62,441
Change (%) 2.24 1.66 5.17 4.05 5.00 2.75 -2.05 -0.05 2.10 6.59 12.09 13.43 12.34 11.13 11.42 15.31 14.63 11.31 9.04
% of Revenue 91.63 92.15 92.13 92.34 92.37 92.50 92.59 92.52 92.80 92.74 92.57 92.39 92.48 92.59 92.71 92.53 92.45 92.13 91.90 91.72
Gross Operating Profit 1,537 1,467 1,495 1,527 1,583 1,630 1,652 1,637 1,568 1,617 1,768 2,032 2,276 2,515 2,748 3,144 3,664 4,397 5,045 5,633
Change (%) -4.59 1.90 2.18 3.62 2.97 1.40 -0.96 -4.18 3.10 9.33 14.93 12.04 10.50 9.25 14.41 16.55 19.99 14.75 11.66
% of Revenue 8.37 7.85 7.87 7.66 7.63 7.50 7.41 7.48 7.20 7.26 7.43 7.61 7.52 7.41 7.29 7.47 7.55 7.87 8.10 8.28
SG&A 793 847 808 862 869 784 901 923 987 1,142 1,189 1,226 1,301 1,373 1,493 1,640 1,834 2,146 2,360 2,646
Change (%) 6.87 -4.63 6.74 0.81 -9.80 14.93 2.43 6.96 15.63 4.15 3.08 6.15 5.54 8.76 9.83 11.81 17.05 9.96 12.12
% of Revenue 4.31 4.53 4.25 4.33 4.19 3.61 4.04 4.22 4.53 5.13 5.00 4.59 4.30 4.04 3.96 3.90 3.78 3.84 3.79 3.89
R&D
Change (%)
% of Revenue
OpEx 17,753 18,190 18,449 19,419 20,175 21,065 21,693 21,245 21,260 21,782 23,188 25,888 29,275 32,798 36,415 40,550 46,705 53,585 59,621 65,048
Change (%) 2.46 1.42 5.26 3.90 4.41 2.98 -2.06 0.07 2.46 6.45 11.64 13.08 12.03 11.03 11.36 15.18 14.73 11.26 9.10
% of Revenue 96.63 97.38 97.14 97.44 97.33 96.93 97.24 97.14 97.56 97.83 97.53 96.96 96.75 96.61 96.64 96.40 96.21 95.96 95.68 95.55
Operating Income 620 489 543 511 554 667 617 626 532 482 587 812 983 1,152 1,267 1,516 1,841 2,258 2,691 3,026
Change (%) -21.17 11.21 -6.06 8.52 20.45 -7.60 1.45 -14.96 -9.35 21.74 38.39 21.04 17.10 10.00 19.66 21.46 22.64 19.19 12.44
% of Revenue 3.37 2.62 2.86 2.56 2.67 3.07 2.76 2.86 2.44 2.17 2.47 3.04 3.25 3.39 3.36 3.60 3.79 4.04 4.32 4.45
Interest Expense -292 -255 -245 -257 -269 -284 -305 -331 -389 -477 -609 -778 -928 -1,044 -1,176 -1,368 -1,513 -1,686 -2,009 -2,283
Change (%) -12.52 -3.87 4.52 4.69 5.81 7.46 8.34 17.58 22.64 27.66 27.75 19.33 12.44 12.69 16.25 10.60 11.48 19.14 13.62
% of Revenue -1.59 -1.37 -1.29 -1.29 -1.30 -1.31 -1.37 -1.51 -1.79 -2.14 -2.56 -2.91 -3.07 -3.08 -3.12 -3.25 -3.12 -3.02 -3.22 -3.35
Net Income 284 225 225 241 266 315 324 298 192 173 186 216 227 214 239 303 446 615 698 782
Change (%) -20.83 0.04 7.08 10.62 18.22 2.86 -7.84 -35.60 -10.18 7.63 16.27 5.11 -5.89 11.98 26.75 47.12 37.75 13.63 11.95
% of Revenue 1.54 1.20 1.18 1.21 1.28 1.45 1.45 1.36 0.88 0.78 0.78 0.81 0.75 0.63 0.63 0.72 0.92 1.10 1.12 1.15

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista